RT Journal Article
SR Electronic
A1 Buckley, Rita
T1 Downregulation of ERCC1 Boosts Efficacy of Platinum-Based NSCLC Chemotherapy
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 3
SP 8
OP 8
DO 10.1177/155989771403003
UL http://mdc.sagepub.com/content/14/3/8.abstract
AB Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) may reduce excision repair cross-complementing group 1 (ERCC1) gene expression, potentially enhancing sensitivity to platinum-based chemotherapy in patients with non—small cell lung cancer (NSCLC), according to results from a poster presented by Cheong et al. [Cheong HT et al. J Thorac Oncol 2014].